Table 3 Survival outcomes assessed by IRC

From: The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial

 

PD-L1 TPS ≥ 1%

PD-L1 TPS < 1%

HR (95% CI)

p-Value

Total (N = 27)

Median PFS

8.61 months

4.73 months

0.8

(0.27–2.35)

0.6817

7.33 months

95% CI

(1.61, -)

(3.61, 11.07)

(3.71–13.67)

Median OS

26.14 months

30.92 months

1.1

(0.34–3.62)

0.8717

30.92 months

95% CI

(8.61, -)

(6.01, -)

(14.75, -)

1-year OS rate

75.0%

66.7%

  

73.9%

95% CI

(31.5, 93.1)

(33.7, 86.0)

  

(50.9–87.3)

2-year OS rate

62.5%

57.1%

  

60.1%

95% CI

(22.9, 86.1)

(25.4, 79.6)

  

(37.2–76.9)

  1. Survival analysis based on the Kaplan–Meier method was used for PFS and OS. A log-rank test was used to compare the difference in survival rate based on PD-L1 expression status. All p-values were two-sided.
  2. IRC independent review committee, HR hazards ratio, 95% CI 95% confidence interval, PFS progression-free survival, OS overall survival.
Back to article page